Enanta Pharmaceuticals Inc (ENTA)

Jun 13, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com

Jun 13, 2025

Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025

Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025

Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025

Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025

Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025

Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025

Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025

Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025

Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025

Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025

Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus

Jun 03, 2025

Jun 03, 2025

Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK

Jun 03, 2025

May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace

May 27, 2025

May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus

May 27, 2025

May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus

May 27, 2025

May 26, 2025

Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech

May 26, 2025

May 24, 2025

Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com Nigeria

May 24, 2025

May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa

May 22, 2025

May 22, 2025

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace

May 22, 2025

May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 - Investing.com

May 22, 2025

May 19, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

May 19, 2025

May 18, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 18, 2025

May 15, 2025

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance

May 15, 2025

May 15, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

May 15, 2025

May 14, 2025

Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus

May 14, 2025

May 14, 2025

ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView

May 14, 2025

May 14, 2025

Enanta stock price target raised to $23 by JMP - Investing.com Canada

May 14, 2025

May 14, 2025

Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks

May 14, 2025

May 13, 2025

Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus

May 13, 2025

May 13, 2025

Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks

May 13, 2025

May 12, 2025

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace

May 12, 2025

May 12, 2025

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

May 12, 2025

May 12, 2025

Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus

May 12, 2025

May 12, 2025

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times

May 12, 2025

May 08, 2025

(ENTA) Trading Report - news.stocktradersdaily.com

May 08, 2025

May 07, 2025

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN

May 07, 2025

May 05, 2025

11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey

May 05, 2025

Apr 27, 2025

JMP Securities maintains Enanta stock with $21 target - MSN

Apr 27, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 23, 2025

(ENTA) Investment Report - news.stocktradersdaily.com

Apr 23, 2025

Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire

Apr 08, 2025

Apr 08, 2025

Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan

Apr 08, 2025

Apr 07, 2025

(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 07, 2025

Apr 05, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025